ROCALTROL CAPSULE

Kraj: Kanada

Język: angielski

Źródło: Health Canada

Kup teraz

Składnik aktywny:

CALCITRIOL

Dostępny od:

SEARCHLIGHT PHARMA INC

Kod ATC:

A11CC04

INN (International Nazwa):

CALCITRIOL

Dawkowanie:

0.25MCG

Forma farmaceutyczna:

CAPSULE

Skład:

CALCITRIOL 0.25MCG

Droga podania:

ORAL

Sztuk w opakowaniu:

100

Typ recepty:

Prescription

Dziedzina terapeutyczna:

VITAMIN D

Podsumowanie produktu:

Active ingredient group (AIG) number: 0113628007; AHFS:

Status autoryzacji:

APPROVED

Data autoryzacji:

2021-01-27

Charakterystyka produktu

                                _ _
_ _
_Page 1 of 25_
PRODUCT MONOGRAPH
PR
ROCALTROL
®
Calcitriol Capsules
Capsules 0.25 mcg and 0.5 mcg
Vitamin D3 Metabolite
Searchlight Pharma Inc.
1600 Notre-Dame Street W. Suite 312
Montreal, Quebec
H3J 1M1
Date of Revision:
January 26, 2021
Submission Control No.: 247457
_ _
_ _
_Page 2 of 25_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................7
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
................................................................................................................10
ACTION AND CLINICAL PHARMACOLOGY
............................................................11
STORAGE AND STABILITY
..........................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................12
PART II: SCIENTIFIC INFORMATION
...............................................................................14
PHARMACEUTICAL INFORMATION
..........................................................................14
CLINICAL TRIALS
..........................................................................................................14
DETAILED PHARMACOLOGY
...................................................
                                
                                Przeczytaj cały dokument
                                
                            

Dokumenty w innych językach

Charakterystyka produktu Charakterystyka produktu francuski 26-01-2021

Wyszukaj powiadomienia związane z tym produktem

Zobacz historię dokumentów